key: cord-0751679-k7xk5x1l
authors: Fenton, Caroline; Keam, Susan J.
title: Emerging small molecule antivirals may fit neatly into COVID-19 treatment
date: 2022-02-28
journal: Drugs Ther Perspect
DOI: 10.1007/s40267-022-00897-8
sha: 8349ee1f630e23e5487894b288d3d1452b3d2929
doc_id: 751679
cord_uid: k7xk5x1l

Numerous treatments exist for COVID-19, the illness caused by SARS-CoV-2 virus, although most are not well established; among these are several small molecule antiviral agents. Intravenous remdesivir is an established treatment worldwide for inpatients and in some countries is also available for use in non-hospitalised high risk patients to prevent progression to severe disease and hospitalization. Oral molnupiravir and oral nirmatrelvir-ritonavir are also available in several countries to prevent progression to severe disease and hospitalization for high-risk outpatients. Many other antiviral small molecules that may have therapeutic potential are under investigation in clinical trials. This article provides a summary of key molecular targets, pharmacology and preliminary data on the efficacy and safety of small molecule antiviral agents being investigated for the treatment of COVID-19.

Much has been learned in the months since the severe acute respiratory syndrome (SARS)-CoV-2 coronavirus, which causes COVID-19, overwhelmed an unprepared world; however, pharmacological treatment options are still very limited [1, 2] . Despite the preferred preventative approach via vaccines, COVID-19 cases still abound [3] . Most cases are mild or asymptomatic, although still contagious [4] . For those more severely affected, COVID-19 treatment aims to reduce viral load and manage and dampen the overexuberant inflammatory response that causes the often fatal acute respiratory distress syndrome (ARDS) and myocarditis [1, 5] .

Essential pharmacological treatment options include antiviral agents (to reduce viral load) as well as immunomodulators and biologics [2] , particularly as it is the inflammatory response and release of proinflammatory cytokines (the "cytokine storm" characteristic of ARDS) rather than SARS-CoV-2 infection per se that is fatal [5] . Of interest, some antiviral agents also act as immunomodulators [1, 6] .

The COVID-19 treatment pipeline includes both "repurposed" agents already approved or developed for other indications and new compounds [1] . Benefits of the former include known adverse drug events and ready availability, but the efficacy of most in COVID-19 has been lacklustre [2, 7] .

In a pandemic setting, reliable bulk manufacture of pharmacological agents is vital; however, it is likely that supply chain issues will arise [8] . Both small molecules and biologics are being studied in COVID-19 [3] . Overall, small molecules tend to be more accessible than biologics due to stability, oral formulation and lower cost ( Table 1) [8] [9] [10] .

This article reviews emerging small molecule antiviral (according to WHO ATC code or EPhMRA code) COVID-19 treatments up to mid-January 2022, with a focus on those furthest along the regulatory pathway. Discussion of the role of other small molecule classes, biologics and older immunomodulators like corticosteroids in the treatment of COVID-19 is outside the scope of this article.

Like other viruses, SARS-CoV-2 infects humans cells by taking over host cell functions ranging from cell entry (to effect viral replication and assembly) to release from host cells ( Table 2 , [1, 13] ). Small molecule antiviral treatments targeting these processes are accordingly broadly grouped into viral entry, replication and release inhibitors (Tables 2  and 3 ) [1] , although the last are so far largely experimental in SARS-CoV-2 [1] .

Most treatment aims to prevent or treat severe COVID-19 in high-risk patients. These include people who are older, obese or pregnant, as well as those with cancer (especially leukaemia or lymphoma), diabetes, or respiratory, cardiovascular and other comorbidities [6] .

Investigations show that cytokines that drive the most severe illness include interleukins (ILs) 2, 6, 7 and 8, tumour Table 1 Comparison of the properties of small molecules and biologics, as reviewed by Ledford [9] and Makurvet [8] ADE adverse drug event, BBB blood-brain barrier, CNS central nervous system, IV intravenous, (k) Da necrosis factor (TNF)-⍺ and interferon (INF)-ɣ [5, 6] ; for some of these cytokines, antagonists already exist [5] . Granulocyte-colony stimulating factor, INF-γ-inducible protein 10, macrophage inflammatory protein 1-α (MIP-1α), and monocyte chemoattractant protein-1 (MCP-1) are also of interest [5] . Clinical trials indicate that a low level of type 1 IFN is also a poor prognostic factor, as are elevated C-reactive protein and D-dimer levels [5, 16] .

The potential for drug resistance, particularly for those to be used as monotherapy, needs to be considered when developing antivirals for the treatment of COVID-19. The propensity of SARS-CoV-2 for drug resistance is inversely proportional to its genetic stability [1] . Although its structural proteins are very stable [14] , the mutations that do occur in the S1 subunit explain some of the increased infectivity of the ⍺, δ and omicron SARS-CoV-2 variants [13, 17] . Despite this, experience with SARS-CoV suggests resistance may not be a significant problem for viral entry inhibitors [1] . Resistance is also less of an issue with agents that directly target host cell, rather than viral, factors (Table 2) . These agents may, helpfully, also reduce ARDS via immune modulation (Table 2) . Nevertheless, resistance to remdesivir (an RdRp inhibitor) has been reported after emergence of an E802D mutation during treatment of an immune-deficient patient with COVID-19 (Table 3 ) [18] .

The choice of antiviral agent may depend on the potential for drug-drug interactions, particularly in patients who are being treated for underlying health issues and therefore may be at high risk of developing severe COVID-19 [19, 20] . Among the small molecule antivirals that are currently available for the treatment of COVID-19, nirmatrelvir-ritonavir [21] [22] [23] has numerous and complex drug-drug interactions (including with over-the-counter medicines and herbal supplements) because of the ritonavir component, which is required to achieve effective nirmatrelvir concentrations (Tables 3 and 4 ). For clinicians who are not experienced in prescribing ritonavir-boosted therapies, consultation with an expert should be considered [24] . In contrast, remdesivir [25, 26] and molnupiravir [27, 28] and their active metabolites do not inhibit or induce major drug metabolising enzymes and are not inhibitors of major drug transporters, so interaction with concomitant medications is unlikely (Tables 3 and 4 ).

Pharmacological features of several approved or almostapproved COVID-19 therapies are still being elucidated (Table 3) , with ideal dosages sometimes unclear [4, 29, 30] . Investigations into several repurposed antivirals, such as favipravir [4, 29, 30] , suggest the plasma and lung concentrations needed to treat COVID-19 may be higher than Table 2 SARS-CoV-2 infective life cycle and key small molecule pharmacological targets, as reviewed by Scudellari [13] and Laws [1] ACE2 angiotensin converting enzyme-2, CK2 casein kinase 2, 3CL PRO 3-chymotrypsin like protease, E envelope, eIF-2α eukaryotic initiation factor 2 alpha, M membrane, M pro main protease, N nucleocapsid, niRAN nidovirus RdRp-associated nucleotidyltransferase, nsp non-structural protein, PL pro papain-like protease, RdRp RNA-dependent RNA polymerase p, S spike, SK sphingosine kinase, TMPRSS2 transmembrane protease serine 2, ↓ decrease(s)/downregulates, ↑ increase(s)/upregulates a Dual effect, also acts as host cell immunomodulator or anti-inflammatory [33] . In vitro activity maintained against SARS-CoV-2 Omicron variant [34] . Several resistance mutations (NSP12 E802D and E802A mutants and NSP6 I168T mutant) identified in vitro [35] ; an E802D mutation has emerged in a patient [18] Absorbed and rapidly metabolised in humans; peak concentration of remdesivir and metabolites in ≤ 2 h Substrate for CYP3A4, metabolite 50% excreted in urine [25, 26] Inhaled formulations of remdesivir have aerosol characteristics consistent with good pulmonary delivery properties in vitro [36] [37] [38] and achieve effective pulmonary drug concentrations in animal models [36] [37] [38] [47] In vitro activity maintained against SARS-CoV-2 variants of concern, including Omicron [34, 51, 52] Phase 1 trial: drug exposure over 10 d at 5× the level predicted to inhibit SARS-CoV-2 viral replication [47] Nirmatrelvir is a CYP3A4 substrate and is mainly eliminated via the kidneys. Coadministration with ritonavir slows metabolism of nirmatrelvir to achieve higher drug concentrations [22, 23] for influenza or HIV and perhaps closer to those required for Ebola treatment [4, 29] . Inhaled formulations of drugs used to treat COVID-19 infection can deliver the drug directly to the site of activity, avoid first-pass metabolism and have less systemic toxicity, so may be of benefit [31] . Clinically, the best constant plasma drug concentration may be at least the identified in vitro EC 90 ; combinations of antivirals are also often preferred [30] . From a safety perspective, the ideal antiviral has an effective or inhibitory trough concentration (EC 50 or IC 50 ) well below the half-cytotoxic concentration [CC 50 ] (Table 3) [4] and will not cause serious adverse drug events at the highest clinically effective dose (Table 4 ). Both the in vitro selectivity index and, especially for oral agents that will be used mostly at home, the clinical therapeutic index [4] are important. At this stage, clinical results (Table 4 ) are driving many decisions [11, 32] .

Currently, the most prominent small molecule antivirals in clinical use are remdesivir [58] , which has full approval for COVID-19 treatment in a number of countries (Tables 3  and 4 ) and molnupiravir and nirmatrelvir-ritonavir, which have either conditional approval or are in the regulatory preregistration or emergency use authorisation (EUA) phase of approval (Tables 3 and 4 ) [20] . Along with dexamethasone, remdesivir is often now the "standard of care" (SOC) comparator in clinical trials (Table 4 ). Lopinavir/ritonavir or hydroxychloroquine were common early SOCs [59] , but newer meta-analyses and reviews do not support their use in COVID-19 [60] [61] [62] Aside from some doubtful SOCs, comparing different agents is complex, as primary endpoints vary and have evolved with emerging understanding of COVID-19 [68] . In early trials, virological cure, preferably measured with the reverse transcription polymerase chain reaction (RT-PCR), was often the primary endpoint, but it was seldom achieved [60, 62] . Clinical primary endpoints are now more [50] Precautions and drug interactions: hepatotoxicity, potential for developing resistance to HIV protease inhibitors in pts with uncontrolled/undiagnosed HIV-1 infection. Numerous drug interactions identified (because of coadministration with ritonavir, which is predominantly metabolized by CYP3A) [21] [22] [23] Contraindications: co-administration with drugs highly dependent on CYP3A for clearance where high levels of those drugs are associated with serious/life-threatening ADEs; coadministration with drugs that are potent CYP3A inducers and therefore reduce plasma levels of nirmatrelvir or ritonavir, which may lead to loss of virological response and the potential for drug resistance [21] [22] [23] Special [57] common (Table 4 ) and these may change during a trial (e.g. to day 29 from the original day 15 primary endpoint in the remdesivir ACCT-1 trial in severe disease [68] ). Recent disappointments (e.g. for AT-527 [88] and eicosapentaenoic acid [7] ) have resulted in a further rethink and/or a focus on narrower patient subgroups [89] . Drug dosages used in the treatment of patients with COVID-19 have also come under the spotlight [73, 90] .

Newer COVID-19 studies are also taking place against a changing patient backdrop. Better understanding of COV-ID-19's clinical course and consequent treatment protocols have contributed to significantly improved patient outcomes since the pandemic started [2, 91] . Between March 2020 and April 2021, COVID-19 mortality rates in selected US hospitals decreased from approximately 18% to 4% and length of stay from 12 to 7 days [92]. In-hospital patient demographics have also changed, with one US study reporting mild disease in almost half of those diagnosed with COVID-19 in early 2021, versus 36% during 2020 [93] .

In terms of patient selection, criteria for mild, moderate and severe disease range from WHO and other ordinal scales to oxygen saturations (SpO 2 %) and/or clinical descriptions [68, 69, 80] . As far as possible, disease severity in Table 4 is based on outpatient or hospital status and SpO 2 as follows:

• mild: non-hospitalised and sometimes asymptomatic, SpO 2 ≥ 95%;

• moderate: hospitalised but not needing active COVID-19 therapy or oxygen, SpO 2 ≥ 94%; • moderate-severe: hospitalised, on supplemental oxygen but not mechanical ventilation, SpO 2 ≥ 93%; or • severe-critical: requiring mechanical ventilation, SpO 2 < 93%.

Two network meta-analyses [60, 62] , which enable comparisons in the absence of head-to-head trials, assessed all-cause mortality, virological cure [60, 62] , mechanical ventilation, hospital discharge and/or adverse drug events in 46 [60] and 222 [62] randomised, controlled trials reported in peer reviewed journals. Proxalutamide, nitazoxanide and remdesivir (Tables 3 and 4 ) improved some outcomes, as did the combination of remdesivir and baricitinib [60, 62] .

Hundreds of small molecule COVID-19 therapy studies are underway [1] , with some preliminary efficacy and tolerability data now available (Table 5 ) and a range of registered trials in progress (Tables 4, 5 and 6). options, as they are usually more easily manufactured, stable, orally available, less costly and may be repurposed from studies or use in viruses other that COVID-19, especially those closely related to SARS-CoV-2. • While COVID-19 treatments are a pressing need, approved medications should meet high efficacy and safety standards and there are many gaps in current knowledge. • Many small molecule antivirals show some promise in selected groups of COVID-19 patients, but large, randomised efficacy and safety studies of both monotherapy and combined antiviral agents are needed. • New small molecule antivirals have been designed with a high barrier for drug resistance; real-world data are required to confirm this. Combination therapy using small molecule antivirals with different mechanisms of action may be required to overcome drug resistance in the future. • Other administration routes for small molecule antivirals, including via inhalation, are a possibility.

Funding The preparation of this review was not supported by any external funding.

Authorship and conflict of interest C Fenton, a contracted employee of Adis International Ltd/Springer Nature, and S Keam, a salaried employee of Adis International Ltd/Springer Nature, declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.

Current trends and future approaches in small-molecule therapeutics for COVID-19

COVID-19) treatment guidelines

Race to a cure

Role of favipiravir in the treatment of COVID-19

The recent outbreaks of human coronaviruses: a medicinal chemistry perspective

Repurposing of anticancer drugs expands possibilities for antiviral and anti-inflammatory discovery in Covid-19

PREPARE-IT 2: icosapent ethyl versus placebo in outpatients with Covid-19: the main results of PREPARE-IT 2

Biologics vs. small molecules: drug costs and patient access

Dozens of coronavirus drugs are in developmentwhat happens next?

Points to consider in drug development of biologics and small molecules

Safety and efficacy of antivirals against SARS-CoV-2

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

How the coronavirus infects cells-and why Delta is so dangerous

Evolution of SARS-CoV-2 envelope, membrane, nucleocapsid, and spike structural proteins from the beginning of the pandemic to September 2020: a global and regional approach by epidemiological week

Structures of SARS-CoV-2 RNA-binding proteins and therapeutic targets

Auxora improves D-dimer levels in patients with severe COVID-19 pneumonia

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles

De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report

Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers

The role of antiviral treatment in the COVID-19 pandemic

Paxlovid: EU summary of product characteristics

Paxlovid: summary of product characteristics

Fact sheet for healthcare providers: emergency use authorization for PAXLOVID TM

National Institutes of Health. The COVID-19 Treatment Guidelines Panel's statement on potential drug-drug interactions between ritonavir-boosted nirmatrelvir (Paxlovid) and concomitant medications

Remdesivir (Veklury): EU summary of product characteristics

Gilead Sciences Inc. VEKLURY-remdesivir injection: US prescribing information

Medicines and Healthcare products Regulatory Agency. Regulatory approval of Lagevrio (molnupiravir)

Fact sheet for healthcare providers: emergency use authorization for molnupiravir

Understanding the pharmacokinetics of favipiravir: implications for treatment of influenza and COVID-19

Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2

Inhalation delivery for the treatment and prevention of COVID-19 infection

Recent progress of antiviral therapy for coronavirus disease 2019

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Nirmatrelvir, molnupiravir, and remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant

In vitro selection of remdesivir resistance suggests evolutionary predictability of SARS-CoV-2

Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro

Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19

Development of remdesivir as a dry powder for inhalation by thin film freezing. Pharmaceutics

AVIGAN tablets 200mg: prescribing information

Unlocking the treatment for mild to moderate Covid-19 in India [media release

beta-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells

Phase 2a, open-label, doseescalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza

Molnupiravir (Lagevrio): EU emergency use approval

Molnupiravir maintains antiviral activity against SARS-CoV-2 variants in vitro and in early clinical studies

Medicines and Healthcare products Regulatory Authority. First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA [media release

Assessment report: use of molnupiravir for the treatment of COVID-19

An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19

Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study [media release

Pfizer reports second-quarter 2021 results [media release

Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death [media release

Structural basis for nirmatrelvir in vitro efficacy against the Omicron variant of SARS-CoV-2. bioRxiv

Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 variants of concern

Kintor Pharma provides update on one of its three multi-regional phase 3 trials of proxalutamide for COVID-19

Evaluation of safety, pharmacokinetics and pharmacodynamics of proxalutamide (GTO918), a potent androgen receptor (AR) blocker, in patients with metastatic brest cancer (mBC): phase 1 dose escalation trial

Alinia (nitazoxanide) oral tablets and suspension: US prescribing information

Romark initiates phase 3 clinical trials of NT-300 for COVID-19 [media release

Romark announces initial results of phase 3 clinical trial of NT-300 tablets for the treatment of COVID-19

What will be the role of molnupiravir in the treatment of COVID-19 infection?

Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: a randomized, phase III clinical trial

Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials

Antiviral therapeutic approaches for SARS-CoV-2 infection: a systematic review

Efficacy of COVID-19 treatments: a Bayesian network meta-analysis of randomized controlled trials

Fact sheet for health care providers emergency use authorization (EUA) oF VEKLURY® (remdesivir)

Early remdesivir to prevent progression to severe Covid-19 in outpatients

Remdesivir for 5 or 10 days in patients with severe Covid-19

Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial

Repurposed antiviral drugs for COVID-19-interim WHO Solidarity trial results

Remdesivir for the treatment of Covid-19-final report

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Baricitinib plus remdesivir for hospitalized adults with COVID-19

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet

Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. medRxiv

openlabeled efficacy study of avifavir in patients with COVID-19

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis

Avifavir for treatment of patients with moderate Coronavirus Disease 2019 (COVID-19): interim results of a phase II/III multicenter randomized clinical trial

Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: a prospective, multicenter, open-label, randomized controlled clinical trial

A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19

Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: a multicenter, open-label, randomized trial

Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia

Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients

Phase 2/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults. NEJM Evidence

Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19. NEJM Evid

Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broadspectrum oral antiviral agent with activity against SARS-CoV-2

Kintor Pharmaceutical receives emergency use authorization for proxalutamide for the treatment of COVID-19 in Paraguay [media release

Efficacy of proxalutamide in hospitalized COVID-19 patients: a randomized, double-blind, placebo-controlled, parallel-design clinical trial

Final results of a randomized, placebo-controlled, two-arm, parallel clinical trial of proxalutamide for hospitalized COVID-19 patients: a multiregional, joint analysis of the Proxa-Rescue AndroCoV trial

Atea Pharmaceuticals provides update and topline results for phase 2 MOONSONG trial evaluating AT-527 in the outpatient setting

Amarin reports overview of latest clinical research evaluating VASCEPA ® /VAZKEPA (icosapent ethyl) and eicosapentaenoic acid (EPA) presented at ESC Congress 2021, organized by the European Society of Cardiology [media release

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

National Center for Health Statistics. In-hospital mortality among hospital confirmed COVID-19 encounters by week from selected hospitals

Our most reliable pandemic number is losing meaning

an oral AXL kinase inhibitor, results in lower mortality compared to standard of care (steroids with or without remdesivir) in hospitalised patients with COVID-19. Two randomised phase 2 studies: BGBC020 and ACCORD2. Online presentation at 31st ECCMID

BerGenBio announces top line data from phase III trial assessing bemcentinib in hospitalised Covid-19 patients [media release

RedHill Biopharma reports further analysis of phase 2/3 data including a 62% reduction in mortality with oral opaganib in moderately severe COVID-19 patients

Sabizabulin for COVID-19: (VERU-111)

Veru reports positive phase 2 clinical results of VERU-111 in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome [media release

High lung levels of active triphosphate predicted with oral AT-527 in COVID patients

AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19

Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial

Senhwa presents positive initial data from phase 2 clinical trial of silmitasertib (CX-4945) in moderate COVID-19 patients at the ISIRV-WHO conference [media release

Sorrento announces encouraging results from two phase 2 studies of abivertinib for treatment of hospitalized severe COVID-19 patients [media release

Brilacidin, a COVID-19 drug candidate, exhibits potent in vitro antiviral activity against SARS-CoV-2. bioRxiv

Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell

Innovation Pharmaceuticals announces topline results from phase 2 clinical trial of brilacidin for COVID-19 [media release

Innovation Pharmaceuticals conducting full data analysis of phase 2 brilacidin COVID-19 trial results to support brilacidin's potential inclusion in governmentsponsored COVID-19 trials [media release

Innovation Pharmaceuticals analyzing full dataset for its brilacidin COVID-19 clinical trial; company evaluating new pipeline opportunities for 2022